Abstract： Primary central nervous system lymphoma (PCNSL) is a type of extranodal non-Hodgkin lymphoma. Whole brain radiation therapy (WBRT) combined with high-dose methotrexate is the standard treatment. Although PCNSL patients are sensitive to radiation therapy, the duration of response is relatively short and it is likely to provoke delayed neurotoxicity, especially in the elderly patients. Reduced-dose WBRT and autologous stem cell transplantation (ASCT) can lower the risk of neurotoxicity, whereas the clinical efficacy remains to be validated. For the elderly patients with PCNSL, application of WBRT in the first-line treatment should be cautiously considered.
Wei Liqun,Yang Liu,Liu Yu et al. The role of whole brain radiation therapy in treatment of primary central nervous system lymphoma:necessary or not[J]. Chinese Journal of Radiation Oncology, 2019, 28(3): 222-225.
[1] Han CH, Batchelor TT. Primary Central Nervous System Lymphoma[J]. Continuum (Minneap Minn),2017,23(6, Neuro-oncology):1601-1618.DOI:10.1212/CON.0000000000000539. [2] Batchelor TT. Primary central nervous system lymphoma[J]. Hematology Am Soc Hematol Educ Program,2016,2016(1):379-385.DOI:10.1182/asheducation-2016.1.379. [3] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2007-2011[J]. Neuro Oncol,2014,16 Suppl 4:v1-v63.DOI:10.1093/neuonc/nou223. [4] Kerbauy MN, Moraes FY, Lok BH, et al. Challenges and opportunities in primary CNS lymphoma:A systematic review[J]. Radiother Oncol,2017,122(3):352-361.DOI:10.1016/j.radonc.2016.12.033. [5] Qian L, Tomuleasa C, Florian IA, et al. Advances in the treatment of newly diagnosed primary central nervous system lymphomas[J]. Blood Res,2017,52(3):159-166.DOI:10.5045/br.2017.52.3.159. [6] Citterio G, Reni M, Gatta G, et al. Primary central nervous system lymphoma[J]. Crit Rev Oncol Hematol,2017,113:97-110.DOI:10.1016/j.critrevonc.2017.03.019. [7] Citterio G, Reni M, Ferreri AJ. Present and future treatment options for primary CNS lymphoma[J]. Expert Opin Pharmacother,2015,16(17):2569-2579.DOI:10.1517/14656566.2015.1088828. [8] Laack NN, Ballman KV, Brown PB, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma:Results of North Central Cancer Treatment Group (NCCTG) 96-73-51[J]. Int J Radiat Oncol Biol Phys,2006,65(5):1429-1439.DOI:10.1016/j.ijrobp.2006.03.061. [9] Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma:cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy[J]. Cancer,2000,89(6):1359-1370. [10] O′Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma:long-term data from a Phase Ⅱ multicenter study (Trans-Tasman Radiation Oncology Group)[J]. Int J Radiat Oncol Biol Phys,2006,64(2):408-413.DOI:10.1016/j.ijrobp.2005.07.958. [11] Ghesquieres H, Ferlay C, Sebban C, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas:a prospective multicentric phase Ⅱ study of the Groupe d′Etude des Lymphomes de l′Adulte (GELA)[J]. Ann Oncol,2010,21(4):842-850.DOI:10.1093/annonc/mdp529. [12] Shapiro WR, Young DF, Mehta BM. Methotrexate:distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections[J]. N Engl J Med,1975,293(4):161-166.DOI:10.1056/NEJM197507242930402. [13] Paydas S. Primary central nervous system lymphoma:essential points in diagnosis and management[J]. Med Oncol,2017,34(4):61.DOI:10.1007/s12032-017-0920-7. [14] Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma:a randomised phase 2 trial[J]. Lancet,2009,374(9700):1512-1520.DOI:10.1016/S0140-6736(09)61416-1. [15] Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on (18) F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy[J]. Oncotarget,2017,8(59):99587-99600.DOI:10.18632/oncotarget.20447. [16] Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma:results of the first randomisation of the International Extranodal Lymphoma Study Group-32(IELSG32) phase 2 trial[J]. Lancet Haematol,2016,3(5):e217-e227.DOI:10.1016/S2352-3026(16)00036-3. [17] Panagiotakos G, Alshamy G, Chan B, et al. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain[J]. PLoS One,2007,2(7):e588.DOI:10.1371/journal.pone.0000588. [18] Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma[J]. J Clin Oncol,2006,24(28):4570-4574.DOI:10.1200/JCO.2006.06.6910. [19] Oh DS, Vredenburgh JA, Reardon DA, et al. Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy[J]. J Radiosurg SBRT,2014,3(1):37-42. [20] Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma[J]. Arch Neurol,2005,62(10):1595-1600.DOI:10.1001/archneur.62.10.1595. [21] Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma[J]. Cochrane Database Syst Rev,2014(6):D9211.DOI:10.1002/14651858.CD009211.pub2. [22] Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis[J]. Ann Oncol,2015,26(7):1305-1313.DOI:10.1093/annonc/mdv076. [23] Kasenda B, Loeffler J, Illerhaus G, et al. The role of whole brain radiation in primary CNS lymphoma[J]. Blood,2016,128(1):32-36.DOI:10.1182/blood-2016-01-650101. [24] Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens[J]. Neuro Oncol,2012,14(1):101-108.DOI:10.1093/neuonc/nor186. [25] Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1):a phase 3, randomised, non-inferiority trial[J]. Lancet Oncol,2010,11(11):1036-1047.DOI:10.1016/S1470-2045(10)70229-1. [26] Doolittle ND, Korfel A, Lubow MA, et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma[J]. Neurology,2013,81(1):84-92.DOI:10.1212/WNL.0b013e318297eeba. [27] Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma:final results and long-term outcome[J]. J Clin Oncol,2013,31(31):3971-3979. [28] Park JS, Lim DH, Ahn YC, et al. Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy[J]. Jpn J Clin Oncol,2017,47(11):995-1001.DOI:10.1093/jjco/hyx120. [29] Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma[J]. Neurology,2002,58(10):1513-1520. [30] Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma:the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy[J]. Cancer,2008,113(5):1025-1031.DOI:10.1002/cncr.23670. [31] Omuro A, Correa DD, Deangelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma[J]. Blood,2015,125(9):1403-1410.DOI:10.1182/blood-2014-10-604561. [32] Ferreri A, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma:results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial[J]. Lancet Haematol,2017,4(11):e510-e523.DOI:10.1016/S2352-3026(17)30174-6. [33] Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma:CALGB 50202(Alliance 50202)[J]. J Clin Oncol,2013,31(25):3061-3068.DOI:10.1200/JCO.2012.46.9957.
2019, Vol. 28 
